RFK Jr. and Elon Musk want to ban pharma ads. They wouldn’t be the first to try

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

FDA approves Novartis’ Cosentyx

Novartis’ Cosentyx hinders interleukin-17A, a cytokine associated with inflammation in HS patients. Credit: Novartis AG. The US Food and Drug Administration (FDA) has granted approval for Novartis’

November 1, 2023

Merck unveils €290m biosafety testing facility in Maryland, US

Merck’s new €290m biosafety testing facility in Rockville features advanced testing capabilities. Credit: Merck/Business Wire. Germany-based Merck KGaA has announced the launch of a new

October 10, 2024

High-Dose Leptin Reversed Severe Genetic Obesity in Two Patients

Personalized recombinant leptin treatment helped reverse severe, early-onset obesity in two children carrying rare antagonistic leptin genetic variants, a study showed. In the double case

June 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.